Why Actuate Therapeutics, Inc.’s (ACTU) Stock Is Down 7.98%
As of Tuesday, May 26, Actuate Therapeutics, Inc.’s ACTU share price has dipped by 7.98%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Commentary & Analysis
Why Actuate Therapeutics, Inc.’s (ACTU) Stock Is Up 14.88%
As of Friday, May 22, Actuate Therapeutics, Inc.’s ACTU share price has surged by 14.88%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Actuate Therapeutics, Inc.’s (ACTU) Stock Is Down 5.98%
As of Thursday, May 21, Actuate Therapeutics, Inc.’s ACTU share price has dipped by 5.98%, which has investors questioning if this is right time to buy.Michael Rose
Why Actuate Therapeutics, Inc.’s (ACTU) Stock Is Up 7.92%
As of Wednesday, May 20, Actuate Therapeutics, Inc.’s ACTU share price has surged by 7.92%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Actuate Therapeutics, Inc.’s (ACTU) Stock Is Up 6.87%
As of Monday, May 18, Actuate Therapeutics, Inc.’s ACTU share price has surged by 6.87%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | ACTU | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $12.7 | $222.9 | 8% |
|
| Shares Out (Mil) | 23.9 | 53.4 | 33% |
|
| Institutional Ownership | 56.0% | 92.9% | 38% |
|
| Float (Mil) | 8.6 | 40.9 | 17% |
|
| Beta | 0.78 | 0.95 | 46% |
|
| Avg Daily Volume (000s) | 475 | 513 | 58% |
|
| Price Change (52-week) |
(92.7%) | 46.3% | 4% |
|
| Growth | ACTU | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.170) | ($0.727) | ($0.663) | |
| Month Ago EPS | ($0.170) | ($0.727) | ($0.663) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.190) | ($0.777) | ($0.850) | |
| Year/Year Chg | (16.7%) | (31.2%) | (34.7%) | |
| Financials | ACTU | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($21) | ($44) | 24% |
|
| EPS (TTM) | ($0.886) | ($1.600) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($20) | ($33) | 15% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $26 | $175 | 12% |
|
| Valuation | ACTU | Industry Median |
Percentile (All Stocks) |
|
| P/B | 13.20 | 2.14 | 93% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ACTU | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.5% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (336.2%) | (47.2%) | 1% |
|
| ROE | na | (53.5%) | na |
|
| Liabilities to Assets | 81.0% | 29.4% | 76% |
|
| F-Score | 3 | 2 | 18% |
|
Actuate Therapeutics, Inc. did not pass any screens on 10/26/2026.
